Benzgalantamine

ZUNVEYL

Open Benzgalantamine in the interactive console ↗

Pronunciation: benz-ga-LAN-ta-meen (ZUN-vayl)

Benzgalantamine ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Benzgalantamine ballicule

Benzgalantamine ZUNVEYL mascot mnemonic cartoon — Visual mnemonic: Benzgalantamine mascot
**“Ben’s galantamine is a Sun veil”**
baby blue theme → muscarinic
sky lantern → galantamine theme

What it isOral galantamine prodrug yielding cholinesterase inhibition; symptomatic treatment of Alzheimer dementia.

Why this oneIts prodrug design reduces direct intestinal exposure while preserving galantamine’s central action.

What limits itBradycardia, syncope, nausea, and weight loss remain possible; benefit is symptomatic and fades when treatment stops.

Benzgalantamine molecular structure (skeletal formula) — Molecular structure: Benzgalantamine

Benzgalantamine prescription history

Animated chart of estimated U.S. prescriptions per year, Dementia meds (1993–2026). Benzgalantamine enters in 2025 (estimated).

FDA-approved for

Alzheimer disease (2024)

Principal riskBradycardia; benefit is symptomatic only

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4

Weight-gain liability0 / 4

Sedation liability1 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Legacy pregnancy categoryN/A (post-2015 labeling)

Defining liabilityCholinergic bradycardia, syncope and gastrointestinal intolerance

FDA label

Read the full label on DailyMed ↗

NO BOXED WARNINGS

FDA dosing	Population	Start	Target	Max
Mild-to-moderate dementia of the Alzheimer's type	Adult	5 mg BID	10 mg BID after ≥4 weeks	15 mg BID

Titration Wait a minimum of 4 weeks at each dose level before increasing

Renal CrCl 9-59 mL/min: do not exceed 10 mg BID; CrCl <9: not recommended

Hepatic Moderate (Child-Pugh 7-9): do not exceed 10 mg BID; severe (10-15): not recommended; no adjustment for mild

Instructions

Swallow whole; do not split, crush, or chew (delayed-release tablet)
Take with or without food; do not take with alcohol
Ensure adequate fluid intake
If interrupted >3 days, restart at lowest dose and re-titrate

Available strengths

DR tab 5, 10, 15 mg

Cautions

Serious skin reactions (Stevens-Johnson syndrome, AGEP) — discontinue at first rash
Vagotonic effects — bradycardia and AV block; dose-related syncope
GI bleeding risk, especially with ulcer history or NSAIDs
Bladder outflow obstruction; seizures; caution in severe asthma/COPD
Increases neuromuscular blockade of succinylcholine-type agents during anesthesia

Adverse reactions

Nausea (21%)
Vomiting (11%)
Diarrhea (7%)
Dizziness (8%), headache (7%)
Decreased appetite/weight

Pregnancy No adequate human data; animal developmental toxicity (skeletal variations, decreased pup growth)

Lactation No human data on benzgalantamine or galantamine in milk

Cost

Benzgalantamine (ZUNVEYL)

Strength		#/mo	CostPlus
5 mg	DR tab	60 BID	not offered
10 mg	DR tab	60 BID	not offered
15 mg	DR tab	60 BID	not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Benzgalantamine is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Active metabolites

Galantamine

Open Benzgalantamine in the interactive console ↗

Memory aids: interaction avatars

Box: minimal PK interactions

Open Benzgalantamine in the interactive console ↗

Self-check

What exposure does benzgalantamine’s prodrug design reduce?
Direct intestinal exposure.
Does benzgalantamine’s symptomatic benefit persist after stopping?
It fades.